Skip to main content

Table 3 Sensitivity analysis and reference levels of inputs

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Name Initial efficacy a Half-life a Decay shape a Vaccine coverage
Reference EPI: 62.5 %, 6-9 months: 79.2 % EPI : 1.12 year, 6-9 months: 1.12 year Exponential EPI: DTP3, 6-9 months: 75 % of DTP3
B Reference Reference Reference Increase 6-9 months to EPI coverage
C Increase (EPI: 80.3 %, 6-9 months: 84.8 %) Reference Reference Reference
D Decrease (EPI: 39.5 %, 6-9 months: 67.3. %) Reference Reference Reference
E Reference Increase (EPI : 3 year, 6-9 months: 3 year) Reference Reference
F Decrease (EPI: 39.5 %, 6-9 months: 67.3. %) Increase (EPI : 3 year, 6-9 months: 3 year) Reference Reference
G Increase (EPI: 80.3 %, 6-9 months: 84.8 %) Increase (EPI : 3 year, 6-9 months: 3 year) Reference Reference
  1. aVaccine efficacy against infection and vaccine half-life of decay against infection